Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
If you have an FSA or HSA, use these for medication costs
Identify hepatotoxic effects of medications using available resources
GLP-1 Receptor Agonist Market Report Snapshot Market Segmentation By Molecule (Liraglutide, Dulaglutide, Semaglutide, Tirzepatide, and Others): The tirzepatide segment earned USD 27.14 billion in 2025, primarily due to superior efficacy in both glycemic control and weight reduction, rapid uptake among healthcare providers, and expanded diabetes and obesity indications, positioning it as a preferred GLP-1 therapy option
This phase 3a trial involving 703 people with type 2 diabetes provides hope that this medication class may be effective when administered orally
PubMed , Molecular and Cellular Biochemistry , vol
US$ 21.22
US$ 20.13
US$ 23.64
US$ 24.49
US$ 20.89
US$ 20.04
US$ 22.96
